Alector, Inc.

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) $206.5 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devasting progression of neurodegeneration, today reported first quarter 2026 financial results and recent portfolio and business updates. As of March 31, 2026, Alector’s cash, cash equivalents, and investments totaled $206.5 million. “Over the past seven years, we have built a highly differentiated blood-brain barrier platform with the versatility to deliver antibodies, enzymes, proteins, and siRNA to the brain,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “We have a rich and growing pipeline of ABC-enabled programs, and we remain deeply committed to developing therapies that can make a meaningful difference for patients living with neurodegenerative diseases.” Recent Program Updates Alector Brain Carrier (ABC): Preclinical and Research Pipeline At the core of Alector’s strategy is the Alector Brain Carrier (ABC), the company’s proprietary platform designed to enhance the delivery of therapeutics to the brain. ABC is intended for peripheral dosing and is adaptable across multiple drug modalities, including antibodies, enzymes, and siRNA. The platform is built on core design principles of versatility, optimized binding properties, and translatability, with the goal of achieving efficient and targeted brain delivery while maintaining a favorable safety profile. Across multiple ABC-enabled programs, preclinical studies have demonstrated robust brain penetration, supporting the advancement of a broad pipeline aimed at addressing the underlying drivers of neurodegenerative diseases. AL037/AL137 Alector continues to advance AL037/AL137, its ABC-enabled anti-amyloid beta (Aβ) antibody program for the treatment of AD, through investigational new drug (IND)-enabling studies. The company is targeting an IND submission in Q1 2027. Both of our AL037 and AL137 candidates are engineered for optimal brain uptake, potency, safety, and convenience. Both candidates comprise the same high-affinity, fully human antibody that selectively binds PyroGlu3, a validated epitope on toxic amyloid beta found in plaques and retain an active effector function intended to facilitate myeloid-mediated plaque clearance. AL037 and AL137 each incorporates Alector’s proprietary ABC technology with TfR binding domains that bind the same epitope on TfR, but with different affinities and binding kinetics, to balance brain penetration and plaque removal with minimized hematologic adverse effects. AL050 Alector continues to progress AL050, its ABC-enabled engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT) for PD, through preclinical development. AL050 is designed to address key challenges associated with enzyme delivery to the brain, featuring an engineered GCase with improved activity and stability and a silenced effector function to maximize safety, paired with Alector’s tunable ABC technology. Preclinical studies to date have demonstrated increased GCase activity and reduced toxic substrate accumulation, supporting its continued preclinical development as a potential therapy for PD and Lewy body dementia (LBD) associated with GBA loss-of-function mutations and subsequently for idiopathic PD and LBD. We continue to evaluate our timeline to the clinic. ABC siRNA Platform Alector is advancing its ABC-enabled siRNA platform with the goal of making treatment more accessible by enabling peripheral dosing as a potential alternative to traditional intrathecal delivery. Alector continues to advance AL064/AL164, its ABC-enabled tau siRNA program for the treatment of AD and other tauopathies. AL064 demonstrated robust tau mRNA knockdown and durable reduction of phospho-Tau 217 in non-human primate studies, and it was subsequently modified to further optimize siRNA stability. This modified form is advancing into IND-enabling studies as AL164. In addition to AL164, the company is advancing early-stage siRNA programs toward lead candidate selection, including ADP062-ABC, an alpha-synuclein siRNA for PD and ADP065-ABC, an NLRP3 siRNA for multiple neurodegenerative conditions, reflecting the broad applicability of the ABC platform across disease mechanisms. Progranulin Program (nivisnebart (AL101/GSK4527226) The global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101/GSK4527226) in early AD has been discontinued following a pre-specified interim futility analysis. An independent data monitoring committee concluded that the trial was unlikely to meet its primary endpoint of slowing disease progression at completion. As the company’s platform and pipeline have continued to evolve, Alector remains focused on the significant opportunities ahead across its ABC-enabled programs. First Quarter 2026 Financial Results Revenue. Collaboration revenue for the quarter ended March 31, 2026, was $1.0 million, compared to $3.7 million for the same period in 2025. The decrease in year-over-year collaborative revenue was primarily due to lower manufacturing-related activity to support the Nivisnebart Phase 2 study in early Alzheimer’s disease. R&D Expenses. Total research and development expenses for the quarter ended March 31, 2026, were $17.9 million, compared to $33.6 million for the quarter ended March 31, 2025. The decrease was mainly due to a decrease in personnel-related costs as a result of the reductions in force as well as a decrease in research and development expenses for the AL002 program. G&A Expenses. Total general and administrative expenses for the quarter ended March 31, 2026, were $8.1 million, compared to $14.7 million for the quarter ended March 31, 2025. The decrease was mainly driven by a decrease in personnel-related costs as a result of the reductions in force. Net Loss. For the quarter ended March 31, 2026, Alector reported a net loss of $22.9 million, or $0.21 per share, compared to a net loss of $40.5 million, or $0.41 net loss per share, for the same period in 2025. Cash Position. Cash, cash equivalents, and investments were $206.5 million as of March 31, 2026. Management anticipates that this will be sufficient to fund Alector’s operations at least through 2027. About Alector Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, expected milestones, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (“SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. Selected Consolidated Balance Sheet Data (in thousands) Condensed Consolidated Statement of Operations Data (in thousands, except share and per share data) Alector Contacts: Argot Partners (media) David Rosen (646) 461-6387 alector@argotpartners.com Argot Partners (investors) Laura Perry (212) 600-1902 alector@argotpartners.com Source: Alector, Inc.

🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as $AVLN on the Nasdaq Thursday with the offering expected to close Friday. It had originally targeted a $182 million IPO. Avalyn is advancing inhaled treatments for rare respiratory diseases. Its lead candidate, called AP01, is in Phase 2 development for progressive pulmonary fibrosis. The company has 51 full-time employees, according to an SEC filing . – Ayisha Sharma 🛑 Alector ends study for GSK-partnered Alzheimer’s drug: The California biotech said it is ending a Phase 2 trial of nivisnebart after an independent committee found it was unlikely to meet the primary endpoint. GSK and Alector plan to discuss their collaboration, which was signed in 2021 and included $1.5 billion in potential milestones. In October last year, another GSK-partnered candidate called latozinemab flunked a Phase 3 study in dementia. Alector’s first-generation antibody-based neurology platform had a separate disappointment in November 2024, when its AbbVie-partnered candidate AL002 failed a Phase 2 Alzheimer’s trial. – Ayisha Sharma 🤝 Teva to acquire Tourette’s drug company for $700M upfront: At the heart of the deal is Emalex’s ecopipam, which is on track for an NDA filing in the second half of the year. Emalex is also eligible for up to $200 million in commercial milestones and royalties. The acquisition reflects Teva’s strategy of focusing on clinically de-risked assets that are “synergistic” with its broader neurology pipeline, CEO Richard Francis told Endpoints News in an interview. But Jefferies analysts wrote that “IP is unclear, given [ecopipam is] an old drug.” – Ayisha Sharma ⏸️ FDA places clinical hold on Newron’s schizophrenia drug: The decision came after the company flagged the sudden death of a patient enrolled in the Phase 3 ENIGMA-TRS 2 trial outside of the US. Newron said an independent board assessed the event and concluded the study should continue as is. The company added it is working to supply the FDA with the necessary information to get the hold lifted. Evenamide targets voltage-gated sodium channels. Newron has previously touted the drug’s strong safety profile as a potential differentiator from standard-of-care antipsychotics. – Ayisha Sharma Merck has discontinued an anti-CTLA-4 program: Known as MK-1308A, the fixed-dose coformulation included Keytruda plus the anti-CTLA-4 antibody quavonlimab. The treatment was part of Merck’s Litespark-012 study that examined combinations with Lenvima in first-line renal cell carcinoma. Merck announced earlier this month that both the MK-1308A regimen and a separate regimen involving Merck’s Welireg failed. — Lei Lei Wu Leo Pharma buys gene therapy player Replay : The deal is for $50 million upfront, and nets Leo a preclinical HSV-based gene therapy for dystrophic epidermolysis bullosa. Replay launched in 2022 with $55 million in seed funding as a hub-and-spoke gene therapy company. — Lei Lei Wu AstraZeneca gets a new protein degrader: The British pharma will license a bispecific antibody degrader from Pinetree Therapeutics, under a $500 million deal inked back in 2024. The candidate, called PTX-299, targets EGFR and has made “encouraging preclinical progress,” the companies announced on Thursday. The move triggers a $25 million payment to Pinetree, and gives AstraZeneca responsibility for future development and commercialization. — Nicole DeFeudis

Two GSK-Alector assets have failed key clinical trials in the past six months.\n GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the study was unlikely to hit its primary endpoint. The study randomized 367 people with early Alzheimer’s to receive one of two doses of the anti-sortilin 1 antibody nivisnebart or placebo. GSK and Alector bet that downregulating the sortilin receptor would elevate levels of progranulin, a protein that supports neurons and microglia in the brain, and thereby improve outcomes in Alzheimer’s. However, a futility analysis found the phase 2 study was unlikely to meet its primary endpoint of slowing disease progression at completion. GSK and Alector responded by stopping the trial and working with investigators to get the news to participants.The result effectively ends Alector’s partnership with GSK, TD Cowen analysts said in a note to investors. GSK paid $700 million upfront to partner with Alector in 2021, securing the right to co-develop two drug candidates. Both molecules have failed key clinical trials in the past six months. Latozinemab, another antibody designed to boost progranulin by blocking sortilin, failed a phase 3 trial in frontotemporal dementia last year. TD Cowen analysts said latozinemab’s failure and discontinuation “led to skepticism about the viability of targeting progranulin.” The discontinuation of the phase 2 trial of nivisnebart, a molecule with the same mechanism as latozinemab, was expected, the analysts said.The setbacks follow the failure of Alector’s AbbVie-partnered Alzheimer\'s prospect in 2024. That drug candidate was designed to activate TREM2, a microglial receptor that genetic and preclinical research suggests plays a central role in Alzheimer’s.TREM2 and progranulin are “exciting targets for microglial activation and neuroprotection,” William Blair analysts said in their own note to investors April 29. While the analysts had been “energized” by the scientific rationale, they said central nervous system penetration of the antibody-based agonists in humans remains an open question. A recent presentation of latozinemab data raised the question again, the analysts said.Alector’s next wave of assets uses technology for crossing the blood-brain barrier. The biotech plans to file to test an anti-amyloid beta antibody that uses the technology in humans in the first quarter of next year. TD Cowen analysts said preclinical data on the technology are “initially promising,” but cautioned that clinical data “remain distant.”